681 Results for "

K. p.

" in MedChemExpress (MCE) Product Catalog:
Products (681)

681 Results for "K. p." in MCE Product Catalog:

1199
1199 Publications Verification
Cat. No.: HY-10108A
CAS No.: 934389-88-5
Purity:  99.93%
Research Areas:  

Cancer

LY294002 hydrochloride is a potent and broad-spectrum PI3K inhibitor, with IC50 values of 0.5, 0.57, and 0.97 μM for P110α, P110δ and P110β, respectively. LY294002 hydrochloride also inhibits CK2 with an IC50 of 98 nM. LY294002 hydrochloride can be used for pancreatic cancer research .
loading...
    loading...
261
261 Cited Publications
Cat. No.: HY-P0175
CAS No.: 1236188-16-1
Synonyms: 740YPDGFR; PDGFR 740Y-P
Target:  

PI3K Autophagy

Research Areas:  

Cancer

740 Y-P (740YPDGFR; PDGFR 740Y-P) is a potent and cell-permeable PI3K activator. 740 Y-P readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone .
loading...
    loading...
90
90 Cited Publications
Cat. No.: HY-15180
CAS No.: 1312445-63-8
Purity:  99.88%
Synonyms: BKM120 Hydrochloride; NVP-BKM120 Hydrochloride
Buparlisib Hydrochloride (BKM120 Hydrochloride) is a CNS-penetrant pan-class I PI3K inhibitor, with IC50 of 52 nM/166 nM/116 nM/262 nM for p110α/p110β/p110δ/p110γ, respectively.
loading...
    loading...
90
90 Cited Publications
Cat. No.: HY-70063
CAS No.: 944396-07-0
Synonyms: BKM120; NVP-BKM120
Target:  

PI3K Apoptosis

Research Areas:  

Cancer

Buparlisib (BKM120; NVP-BKM120) is a pan-class I PI3K inhibitor, with blood-brain barrier permeability. Buparlisib has IC50s of 52, 166, 116 and 262 nM for p110α, p110β, p110δ and p110γ, respectively .
loading...
    loading...
78
78 Cited Publications
Cat. No.: HY-12005
CAS No.: 162359-56-0
Purity:  99.95%
Synonyms: FTY720
Target:  

LPL Receptor PAK

Research Areas:  

Inflammation/Immunology Cancer

Fingolimod (FTY720) hydrochloride is a sphingosine 1-phosphate (S1P) antagonist with IC50 of 0.033 nM in K562 and NK cells. Fingolimod hydrochloride is also a pak1 activator and immunosuppressant .
loading...
    loading...
78
78 Cited Publications
Cat. No.: HY-11063
CAS No.: 162359-55-9
Purity:  99.97%
Synonyms: FTY720 free base
Fingolimod (FTY720 free base) is a brain-penetrant sphingosine 1-phosphate (S1P) antagonist with an IC50 of 0.033 nM in K562 and NK cells. Fingolimod also is a pak1 activator, a immunosuppressant .
loading...
    loading...
71
71 Cited Publications
Cat. No.: HY-50673
CAS No.: 915019-65-7
Synonyms: BEZ235; NVP-BEZ235
Target:  

PI3K mTOR Autophagy

Research Areas:  

Cancer

Dactolisib (BEZ235) is an orally active and dual pan-class I PI3K and mTOR kinase inhibitor with IC50s of 4 nM/5 nM/7 nM/75 nM, and 20.7 nM for p110α/p110γ/p110δ/p110β and mTOR, respectively. Dactolisib (BEZ235) inhibits both mTORC1 and mTORC2.
loading...
    loading...
68
68 Cited Publications
Cat. No.: HY-50094
CAS No.: 957054-30-7
Synonyms: GDC-0941
Target:  

PI3K Autophagy Apoptosis

Research Areas:  

Cancer

Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with an IC50 of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold).
loading...
    loading...
68
68 Cited Publications
Cat. No.: HY-20180
CAS No.: 957054-33-0
Synonyms: GDC-0941 dimethanesulfonate ; GDC-0941 (2 MeSO3H salt)
Target:  

PI3K Autophagy Apoptosis

Research Areas:  

Cancer

Pictilisib dimethanesulfonate (GDC-0941 dimethanesulfonate) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold).
loading...
    loading...
67
67 Cited Publications
Cat. No.: HY-50673A
CAS No.: 2319647-83-9
Synonyms: BEZ235 hydrochloride; NVP-BEZ235 hydrochloride
Target:  

PI3K mTOR Autophagy

Research Areas:  

Cancer

Dactolisib (BEZ235) hydrochloride is an orally active, dual pan-class I PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR with IC50 of 4 nM/5 nM/7 nM/75 nM and 20.7 nM, respectively. Dactolisib hydrochloride (BEZ235) inhibits mTORC1 and mTORC2 .
loading...
    loading...
64
64 Cited Publications
Cat. No.: HY-18234A
CAS No.: 103476-89-7
Leupeptin hemisulfate is a broad-spectrum protease inhibitor. Leupeptin hemisulfate inhibits serine, cysteine and threonine proteases, and regulates autophagy. Leupeptin hemisulfate reduces the expression levels of LC3B, iNOS, Cox-2, Beclin-1 and the level of endopeptidases; increases the levels of p62, Arg 1, Msr 1 and Mrc 1; and blocks the upregulation of p-PTEN, p-NF-κB, p-PI3K, p-Akt, p-p38 and ERK1/2. Leupeptin hemisulfate inhibits NO, ROS, proinflammatory cytokines, the IFN-γ/IL-10 ratio, phagolysosome fusion, mammalian lysosomal hydrolase activity and SARS-CoV-2 replication; and reverses impaired autophagic flux. Leupeptin hemisulfate is applicable to research related to chronic inflammatory diseases, edema, skin tumorigenesis, COVID-19 and respiratory infections .
loading...
    loading...
57
57 Cited Publications
Cat. No.: HY-13026
CAS No.: 870281-82-6
Purity:  99.69%
Synonyms: CAL-101; GS-1101
Target:  

PI3K Autophagy

Research Areas:  

Cancer

Idelalisib (CAL-101; GS-1101) is a highly selective and orally bioavailable p110δ inhibitor with an IC50 of 2.5 nM, showing 40- to 300-fold selectivity for p110δ over other PI3K class I enzymes.
loading...
    loading...
52
52 Cited Publications
Cat. No.: HY-15676
CAS No.: 1229705-06-9
Purity:  99.93%
Synonyms: RG7388
Idasanutlin (RG7388) is an orally bioavailable MDM2 inhibitor with an IC50 of 6 nM. Idasanutlin disrupts MDM2-p53 binding, stabilizes and activates p53, triggering cell cycle arrest, apoptosis, and reduced cancer cell viability. Idasanutlin reduces EGFR protein expression and phosphorylation, suppresses downstream SHP2, MEK1/2, ERK1/2, AKT, mTOR, p70(S6K1), and S6 signaling. Idasanutlin induces mitochondrial ROS production, drives p38 MAPK phosphorylation, upregulates NOXA, and mediates caspase-3-dependent apoptosis and gasdermin E-mediated pyroptosis. Idasanutlin can be used for the research of TP53-mutant non-small cell lung cancer, T-cell acute lymphoblastic leukemia, colorectal carcinoma, melanoma, diffuse large B-cell lymphoma, mantle cell lymphoma, non-Hodgkin lymphoma, severe fever with thrombocytopenia syndrome, neuroblastoma, acute lymphoblastic leukemia, relapsed or refractory acute myeloid leukemia, osteosarcoma, solid tumors, and hematological tumors .
loading...
    loading...
33
33 Cited Publications
Cat. No.: HY-10115
CAS No.: 371935-74-9
Purity:  99.82%
Research Areas:  

Cancer

PI-103 is a potent PI3K and mTOR inhibitor with IC50s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for p110α, p110β, p110δ, p110γ, mTORC1, and mTORC2. PI-103 also inhibits DNA-PK with an IC50 of 2 nM. PI-103 induces autophagy .
loading...
    loading...
33
33 Cited Publications
Cat. No.: HY-10115A
CAS No.: 371935-79-4
Purity:  98.55%
Research Areas:  

Cancer

PI-103 Hydrochloride is a dual PI3K and mTOR inhibitor with IC50s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for p110α, p110β, p110δ, p110γ, mTORC1, and mTORC2. PI-103 Hydrochloride also inhibits DNA-PK with an IC50 of 2 nM. PI-103 Hydrochloride induces autophagy .
loading...
    loading...
28
28 Cited Publications
Cat. No.: HY-15206
CAS No.: 10238-21-8
Purity:  99.94%
Synonyms: Glyburide
Glibenclamide (Glyburide) is an orally active ATP-sensitive K + channel (KATP) inhibitor and can be used for the research of diabetes and obesity . Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR) . Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability . Glibenclamide can induce autophagy .
loading...
    loading...
21
21 Cited Publications
Cat. No.: HY-N0484
CAS No.: 2586-96-1
Liensinine is a bisbenzylisoquinoline alkaloid. By inhibiting the PI3K/AKT and JNK/p38-MAPK signaling pathways, Liensinine suppresses autophagy and apoptosis, clears , and exerts anti-inflammatory, antioxidant and neuroprotective effects. Liensinine activates AMPK and inhibits the expression of HIF-1α and VEGF, thereby suppressing angiogenesis. Liensinine exerts anti-tumor effects through ROS-mediated inhibition of the JAK2/STAT3 signaling pathway. Liensinine can be used for the research of diseases such as Alzheimer's disease, hepatocellular carcinoma, osteosarcoma, sepsis-induced organ injury and stroke .
loading...
    loading...
21
21 Cited Publications
Cat. No.: HY-N5014
CAS No.: 2385-63-9
Liensinine perchlorate is a bisbenzylisoquinoline alkaloid. By inhibiting the PI3K/AKT and JNK/p38-MAPK signaling pathways, Liensinine perchlorate suppresses autophagy and apoptosis, clears , and exerts anti-inflammatory, antioxidant and neuroprotective effects. Liensinine perchlorate activates AMPK and inhibits the expression of HIF-1α and VEGF, thereby suppressing angiogenesis. Liensinine perchlorate exerts anti-tumor effects through ROS-mediated inhibition of the JAK2/STAT3 signaling pathway. Liensinine perchlorate can be used for the research of diseases such as Alzheimer's disease, hepatocellular carcinoma, osteosarcoma, sepsis-induced organ injury and stroke .
loading...
    loading...
20
20 Cited Publications
Cat. No.: HY-10297
CAS No.: 1086062-66-9
Purity:  99.94%
Synonyms: GSK2126458; GSK458
Target:  

PI3K mTOR Autophagy

Research Areas:  

Cancer

Omipalisib (GSK2126458) is an orally active and highly selective inhibitor of PI3K with Kis of 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM for p110α/β/δ/γ, mTORC1/2, respectively. Omipalisib has anti-cancer activity .
loading...
    loading...
19
19 Cited Publications
Cat. No.: HY-P0118
CAS No.: 272105-42-7
Synonyms: P144
Research Areas:  

Cancer

Disitertide (P144) is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide (P144) is also a PI3K inhibitor and an apoptosis inducer .
loading...
    loading...